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ABSTRACT: SARS-CoV-2 has infected over 128 million people worldwide, and until a
vaccine is developed and widely disseminated, vigilant testing and contact tracing are the most
eﬀective ways to slow the spread of COVID-19. Typical clinical testing only conﬁrms the
presence or absence of the virus, but rather, a simple and rapid testing procedure that
sequences the entire genome would be impactful and allow for tracing the spread of the virus
and variants, as well as the appearance of new variants. However, traditional short read
sequencing methods are time consuming and expensive. Herein, we describe a tiled genome
array that we developed for rapid and inexpensive full viral genome resequencing, and we have
applied our SARS-CoV-2-speciﬁc genome tiling array to rapidly and accurately resequence the
viral genome from eight clinical samples. We have resequenced eight samples acquired from
patients in Wyoming that tested positive for SARS-CoV-2. We were ultimately able to
sequence over 95% of the genome of each sample with greater than 99.9% average accuracy.

■

INTRODUCTION
To date, there have been over 128 million conﬁrmed cases and
nearly 2.8 million deaths worldwide due to COVID-19, caused
by the severe acute respiratory syndrome coronavirus 2 (SARSCoV2).1 COVID-19 is highly contagious and rapidly spread
within the human population and was deﬁned as a global
pandemic in March 2020 by the World Health Organization.
Vigilant testing and tracing are essential for controlling the
SARS-CoV-2 virus, so a technology to monitor the evolution
of the viral genome and the emergence of virus variants and
detect possible transmission chains is highly desirable.2,3 Such
a technique requires a rapid, inexpensive, and accurate tool
that can detect genetic variants within the SARS-CoV-2
genome with single base resolution.
Next-generation sequencing (NGS) methods for sequencing
the viral genome are established and accurate. However, it is
hard to take advantage of the throughput of NGS by
multiplexing a large number of samples, and major costs are
associated with library preparation. Therefore, the cost of NGS
sequencing of viral genomes is relatively high (cost per
assembled base of a viral genome is ∼10 000 times more
expensive than the human genome). To remedy this problem,
a number of studies have demonstrated the capability of DNA
arrays in the detection,4 surveillance,5,6 and screening of
multiple viral strains, including coronavirus.7,8 However, DNA
arrays originally only used a limited number of oligonucleotide
features, leading to a bias in genome coverage. However,
© 2021 American Chemical Society

improvements in DNA array technology and decreasing
production costs led to the development of whole genome
tiling arrays with high-density oligonucleotide features that
cover each base in the genome with sense and antisense probes
to the genome of interest.9,10 These tiling arrays can be applied
to resequence the genome (identify single nucleotide variants)
from clinical samples at a very low cost.11,12
Here, we describe a full genome tiling array with more than
240 000 features that provide 2× coverage of the entire SARSCoV-2 genome and the use of such a genome tiling array to
sequence the genome from eight clinical samples from SARSCoV-2-positive subjects. Our results indicate that we can
sequence at least 95% of the viral genome with on average
greater than 99.9% accuracy.

■

EXPERIMENTAL SECTION

Sample Preparation for Illumina Sequencing. Samples were
prepared as previously described using the ARTIC sequencing
methods. In brief, cDNA was prepared from total RNA extracted
from clinical samples using SuperScript IV (SSIV, Thermo Scientiﬁc)
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Figure 1. (A) ∼30 000 base SARS-CoV-2 genome. (B) Zoomed into the N gene of the SARS-CoV-2 genome covering ∼2000 bases. (C) Position
28 274-29 533 of the SARS-CoV-2 genome, which is ampliﬁed by the CDC N1 primers. (D) Three diﬀerent sense probe sets; each probe set
consists of four features synthesized on the genome tiling array to interrogate the middle base position (highlighted in red font). The feature whose
sequence is consistent with the reference (NC_045512.2) is highlighted in bold and denoted with an asterisk. (E) Extracted regions from the tiling
array for genome positions 29 319-29 321 and 28 322-28 325 illustrating how the feature with the highest intensity is used to call the base at each
position in the SARS-CoV-2 genome. (F) An image illustrating the resulting confocal scan of the genome tiling array when hybridized to a SARSCoV-2 sample. One alignment marker is highlighted, which is used for correctly extracting the intensities for each probe set.
and random hexamer priming. The resultant cDNA was ampliﬁed in
two polymerase chain reaction (PCR) reactions using the ARTIC
Pool1 and Pool2 SARS-CoV-2 v3 primer sets and Q5 high ﬁdelity
DNA polymerase (NEB). Following PCR, samples were puriﬁed
using AMPure XP SPRI beads (Beckman Coulter). Illumina adaptors
were added using the NEBNext Ultra II DNA Library Prep Kit
(NEB), and SPRI bead puriﬁcation was repeated.
Sample Preparation for Sequencing on Chips. To prepare
samples for hybridization to the chips, 0.05 μL of the puriﬁed PCR
product was ampliﬁed using the ARTIC protocol and Pool1 and
Pool2 v3 primer sets for 35 cycles with 50 μM biotin-11-dUTP (Jena
Biosciences) added to the reaction mixture. Pool1 and Pool2 were
combined for each sample and fragmented using DNase I (D4263,
Sigma-Aldrich). Two thousand Kunitz units of lyophilized DNase I
was resuspended on ice using 2 mL of 1× DNase I Buﬀer (10 mM
Tris−HCl pH 7.5, 2.5 mM MgCl2, 0.1 mM CaCl2). The resuspended
enzyme was diluted 1000-fold using 1x DNase I Buﬀer, and an equal
volume was added to samples prewarmed to 37 °C. Samples were
incubated for 30 min at 37 °C, and the reactions were stopped by
adding ethylenediaminetetraacetic acid (EDTA) to a ﬁnal concentration of 12.5 mM and incubating for 20 min at 75 °C.
Hybridization. Forty-ﬁve microliters of the fragmented sample
was hybridized overnight at 45 °C to the chip in a 60 μL ﬁnal volume
containing 5 mM EDTA, 6.25 mM HEPES pH 8.0, 312.5 mM NaCl,
1.25% Ficoll 400, 0.5 nM Cy3-AM1 (GCTGTATCGGCTGAATCGTA). Following hybridization, chips were washed for 10 min at room
temperature in Wash A (2× SSC, 0.1% TWEEN-20) and then for 10
min at 39 °C in Wash B (0.5×SSC, 0.1% TWEEN-20). Chips were
stained for 15 min at room temperature using 0.02 mg/mL Cy3-

Streptavidin (Thermo) in 4× SSC and washed for 5 min at room
temperature using 4× SSC. Chips were scanned using a custom-built
confocal scanner for 0.5, 1, 4, and 8 s in the green (Cy3) channel in
4× SSC.
Reverse Transcription Polymerase Chain Reaction (RT-PCR)
Using the CDC N1 and N2 Primer Sets. RT-PCR was performed
using the CDC N1 and N2 primer sets. Five hundred copies of the
SARS-CoV-2 genome (Twist Biosciences) were ampliﬁed in a 25 μL
reaction volume using the SuperScript IV One-Step kit (Thermo
Fisher) containing 250 nM of each primer (Primer mix 1−152), 50
μM biotin-11-dUTP (Jena Biosciences), and 0.5 μL of RT enzyme
mix. Cycling was performed as follows: 12 min at 45 °C, 2 min at 98
°C, 40 cycles of 10 s at 98 °C, 11 s at 61 °C, and 11 s at 72 °C,
followed by a ﬁnal extension of 2 min at 72 °C. The PCR product was
hybridized to the array as described above with one modiﬁcation:
hybridization was performed for 90 min instead of overnight.
Base Calling Approach. Base Calling for N1 and N2 Amplicon
Experiments. RT-PCR products are hybridized to chips and imaged
on the custom-built confocal scanner. A synthetic alignment marker
sequence, “Cy3-AM1”, is added to the hybridization mixture
containing the RT-PCR products and hybridization buﬀer. This
sequence hybridizes in a square pattern at predetermined regularly
spaced locations across the chip, as illustrated in Figure 1. The images
are stitched together and gridded to create a composite image and
using the positional information from the Cy3-AM1 sequences, and
intensities for each feature on the chip are extracted from the image
and stored in a. csv text ﬁle. Each base has two corresponding probe
sets: one for the sense strand and one for the antisense strand. Each
probe set consists of four features, one for each base, ATCG; thus,
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Figure 2. Development of the maximum likelihood base caller for SARS-CoV-2 genome sequencing using full genome tiling arrays. (A) Density
plot derived from a two-dimensional (2D) histogram of the incorrect calls from all tiling array probe sets including sense and antisense data for a
single exposure. This image was constructed by “calling” each base in the genome using all probe sets. With this approach, each base is called twice,
once from the sense probe sets and once from the antisense probe sets. The diﬀerence and diﬀerential of a call are included in the histogram if the
base call does not match the reference. Contours indicate a likelihood function proportional to the two-dimensional cumulative sum of the density;
the sum is normalized to indicate the fraction of wrong calls whose quality parameters are higher than the given point; higher values indicate a
higher likelihood that a call is “wrong”. (B) Same as A, except the 2D histogram is for the correct calls from all tiling array probe sets. Contours
indicate a cumulative sum of the density, normalized to indicate the likelihood that a call is correct. It can be observed that the distribution of the
diﬀerence and diﬀerential of “correct” calls is very diﬀerent from the “incorrect” calls. (C) Using the observation from panels A and B, we
constructed a function to assign the likelihood that a probe set is calling the correct base for a given position. The dotted contours deﬁne the
(combined) likelihood that a probe set is correctly calling the correct base, based on the diﬀerence and diﬀerential score for that probe set. The
triangle points on the plot illustrate the diﬀerent and diﬀerential values for probe sets for all variant sites that have been reported in Wyoming
samples in the GISAID database as of August 2020. The green triangles indicate that the base call from this scan suggests a reference call, whereas a
red triangle indicates that the call suggests a nonreference base at this position. If the triangle points up, this is from the sense probe set, whereas a
downward pointed triangle indicates the data is for the antisense probe set. The triangle outline is ﬁlled in if this probe set from this scan resulted in
the highest likelihood for the correct call among all scans for this position. This image is the 4 s scan of the WY64 sample. To call all of the bases,
we construct a similar likelihood function for each scan, and this information was combined as described in the methods to make the ﬁnal base call.
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Figure 3. Sequencing accuracy across the SARS-CoV-2 genome. (A) The Phred score (left axis) for all bases in the SARS-CoV-2 genome from the
tiling array full genome sequencing of WY64. The positions of all variant calls are highlighted by Black “X”, and a Red X indicates this is a correct
variant call (conﬁrmed by the Illumina short read sequencing data). The cumulative sum of noncalls (blue line), variant calls with a Phred score
greater than 20 (cyan line), and variant calls that have a Phred score greater than 20 and pass the low coverage ﬁlter (red line) is shown on the
secondary Y-axis. (B) Comparison of the tiling array genome sequencing quality scores and variant calls to the amplicon coverage from short read
Illumina sequencing data. The light blue (right axis) lines indicate the sequence coverage from the WY64 sample, and the dark blue lines indicate
the average sequencing coverage over all Wyoming GISAID samples as of 8/2020.
Whole Viral Genome Base Calling Using Likelihood Maps for
Multiple Exposures. Multiple successive images (0.5, 1, 4, and 8 s
exposures) are taken for one chip, resulting in a set of NE measures
(typically NE = 3 or 4). For each position within the genome, we
obtain 2NE sets (sense and antisense) of four intensities {Ij⃗ }j = 1···2NE, I ⃗
= [IA,IT,IC,IG]. The intensities within each set are sorted Imax ≡ I3 ≥ I2
≥ I1 ≥ I0 ≡ Imin, and the base corresponding to the highest one is
tentatively called for the respective location. Ideally, the call from each
of the sets would indicate the same base, but this is not always the
case. We use the diﬀerence D ≡ Imax − Imin, diﬀerential drel ≡ (Imax −
I2)/D, and signal magnitude Imax = I3 to assign a credibility score to
each base call from the sense and antisense probe sets at each
exposure.
We follow a Bayesian-inspired approach, where we rely on a
reference genome to indicate whether a preliminary call is likely

there are a total of eight features per base position. The intensity for
each feature is stored in the. csv ﬁle. Feature intensities within a probe
set are ranked separately for the sense and antisense probe sets for
each base (I3 ≥ I2 ≥ I1 ≥ I0). The diﬀerence (D = I3 − I0) and

(

diﬀerential drel =

I3 − I2
D

) are calculated for the sense and antisense

probe sets separately.
A putative base is called for the probe set with the highest intensity
for the sense set and separately for the antisense set. If the diﬀerential
is smaller than a threshold (2% default) and/or if the diﬀerence is
smaller than a threshold (20 for low-intensity chips or 100 for highintensity chips), the base is called “N” for unknown. If a base is not
called N, the diﬀerentials for sense or antisense set are compared, and
the set with a larger diﬀerential is used to call the base. FASTA ﬁles
are generated from these parameters and aligned to references.
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Table 1. Sequencing Accuracy and Coverage for the Eight Clinical Samplesa
Q20 ﬁlter

low coverage ﬁlter

sample

noncalls

variants

accuracy

coverage

noncalls

variants

accuracy

coverage

illumina coverage

WY24
WY26
WY32
WY36
WY41
WY44
WY59
WY64

353
493
615
354
810
266
570
183

39
47
48
52
68
33
57
27

99.89%
99.87%
99.86%
99.85%
99.79%
99.92%
99.83%
99.94%

98.82%
98.35%
97.94%
98.82%
97.29%
99.11%
98.09%
99.39%

1404
1431
1473
1365
1709
1295
1512
1247

36
35
32
36
49
26
41
16

99.90%
99.90%
99.92%
99.90%
99.85%
99.94%
99.88%
99.97%

95.30%
95.21%
95.07%
95.43%
94.28%
95.66%
94.94%
95.83%

99.86%
99.07%
99.76%
99.07%
99.59%
99.00%
98.63%
99.18%

a
The number of “noncalls” refers to the number of base positions that were not called (or removed) because they have a Phred score lower than 20
or reside in one of the six lowest short read Illumina sequencing coverage regions. “Variants” is the number of putative variants from the sample
called by the genome tiling array sequencing. “Accuracy” is the number of correctly called positions divided by the number of base calls. “Coverage”
refers to the percentage of the SARS-CoV-2 genome for which we have called a base. The “illumina coverage” column refers to the sequencing
coverage of the samples in the GISAID database.

correct. After identifying the base with the highest intensity for each
of 2NG sets for a given exposure time, we group the sets into two
groups, those that match the reference call and those that do not
(Figure 2). The distributions of the “quality parameter” values (D,drel)
for these groups follow diﬀerent geometric patterns, as illustrated in
Figure 2. Each of the parameters taken separately is informative, in
that higher values indicate higher conﬁdence that a call is correct.
However, the geometry of the distributions in Figure 2A,B illustrates
the diﬃculties associated with comparing two calls, where one has a
higher absolute diﬀerence and the other has a higher relative
diﬀerential.
To illustrate our methods, the likelihood score using one quality
parameter is described. If we rely on one quality parameter x, which
could be one of D,drel,Imax to infer the likelihood that a read is correct,
we can make the following argument. Without knowledge of the
quality parameter x, the probability that a call is correct is
approximated by the fraction of calls that are correct, Pcorrect ≈
Ncorrect/Ntotal. Regarding the dependence on x, ﬁrst note that the
likelihood that a call is correct increases with x, that is, a call with
parameter value x′ > x is more likely correct than the one with x.
Second, given that a call is correct, its parameter x follows some
(continuous) distribution ρcorrect (x). This local density of correct calls
is not a good estimate that a call is correct since it will decrease as x
increases beyond the location of the peak density. The local
probability that a call is correct should follow from the ratio of the
local density of correct calls to that of all calls (correct and incorrect);
however, these are too small to estimate far away from the center of
the respective distributions.
We assign a likelihood that a call with parameter value x = λ is
correct by comparing the fraction of correct calls with lower or higher
x values. If the likelihood of a call being correct increases with x, then
all of the calls with x < λ are less likely and those with x > λ are more
likely to be correct. A call whose x exceeds that of all correct calls is
assigned the full probability Pcorrect. Thus, the likelihood that a call
with parameter x is correct is (conservatively) estimated by
x
lcorrect(x) = Pcorrect ∫ min ρcorrect (x′)dx′.
x
xmin

=

Ncorrect
Ntotal

=

ncorrect(x ′ ≤ x)
Ntotal

∫x

wcorrect(D , drel) ≡ ncorrect(D′ ≤ D , d′rel ≤ drel), wincorrect(D , drel)
= nincorrect(D′ ≥ D , d′rel ≥ drel)
Without knowledge of its quality parameters (x,y) = (D,drel), the
probability that a given call is correct is approximated by Ncorrect/Ntotal.
We assume that a call with parameters (x,y) is more likely to be
correct than a call with lower parameters x′ ≤ x,y′ ≤ x. Let ρcorrect
(x,y) denote the normalized probability density for correct calls in two
dimensions. Given that a read is correct, the probability that its quality
parameters are both below (x,y) is
P(x′ ≤ x , y′ ≤ y|for a correct call) =
dx′, dy′ ≈

min

min

ρcorrect (x′, y′)

ncorrect (x′ ≤ x , y′ ≤ y)
Ncorrect

■

A similar argument can be made for the likelihood that the call is
wrong, except this will decrease as x increases, working out to
lincorrect(x) = nincorrect(x′ ≥ x)/Ntotal . We obtain a normalized score

RESULTS AND DISCUSSION
SARS-CoV-2 Genome Tiling Arrays. We have constructed a genome tiling array of the SARS-CoV-2 genome
(NC_045512)13 (Figure 1A). The 3 mm × 3 mm array area is
divided into 250 000 “features”. Each feature contains densely
packed identical single strands of DNA, each 25 bases long and

lcorrect
.
lcorrect + l incorrect

To use two parameters, we construct a credibility score that maps a
pair of parameters (D,drel) to a continuous value between [0,1] as
wcorrect
S= w
, where
+w
+1
correct

y

Thus, wcorrect (D,drel)/Ntotal approximates the probability that a call is
correct and has quality parameters equal or worse than (D,drel).
Eﬀectively, this approach assumes that the likelihood that a read with
D,drel is correct is proportional to the number of reference-matching
reads with both D′ ≤ D and d′ref ≤ dref. Similarly, wincorrect (D,drel)/
Ntotal approximates the probability that a call is wrong and has equal
or better (higher) quality parameters.
For calls whose parameters are above those of every nonmatching
call, wincorrect = 0. We added the oﬀset term in the denominator of S to
avoid a “perfect” score S = 1 for such calls, so their rank among
correct calls is still taken into account.
The score S(D,drel) described above is calculated eﬃciently for
every read of every base using a 2D histogram of the distributions of
matching and nonmatching calls. The raw bin counts are converted
into a smoothened local density obtained as a moving average over
neighboring bins, and the averages are used to compute cumulative
sums in both directions. Each read is assigned a score corresponding
to the 2D bin into which it falls. Reads for a given genome location
are sorted by their score, and the ﬁnal call is made consistent with the
top-scoring read. The S score is interpreted as the likelihood that the
read is correct.
FASTA ﬁles for sequencing results generated from microarray
images are aligned to the reference sequences for SARS-CoV-2 and
human RNase P, NC_045512.2 Wuhan seafood market pneumonia
virus isolate Wuhan-Hu-1, complete genome (GISAID accession
EPI_ISL_402125).

ρcorrect (x′)dx′

by combining the two likelihoods:S(x) =

x

∫x ∫y

incorrect
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Figure 4. (A) Average number of variant base calls across all eight samples as a function of the genome coordinates. The cumulative sum of the
number of variants identiﬁed is displayed on the secondary axis. The ∼300 base region between 19 300 and 19 600 is where the largest number of
putative variants are called. (B) Same as panel (A), except the x-axis spans the region between base positions 19 100 and 19 700. Bars indicate
variant calls by sample and location. The cumulative sum reﬂects the number of variant calls across all samples. (C) The maximum signal intensity
from all exposure scans from the chip as a function of genome coordinate [same range as (B)]. From this panel, it can be seen that the maximum
signal intensity (for all samples) on the genome tiling array is low in the region from bases 19 300 to 19 600. This region corresponds to the low
coverage region from the short read Illumina sequencing data (see Figure 3B). (D) The Phred score of the ﬁnal base calls from the tiling array as a
function of the genome coordinate.

image (Figure 1F) the positions of the hybridized genome
molecule “light up” and the base can be identiﬁed. There is the
possibility of an error if there is more than one region within
the genome with identical 25-mer sequences; however, the
probability of this occurring is vanishingly small for a sequence
of 30 000 bases.
Although the SARS-CoV-2 genome is a single-stranded
RNA, during the processing of the clinical sample, the genome
is reverse-transcribed and ampliﬁed generating a doublestranded DNA. Therefore, the genome tiling arrays were
constructed to assay both the sense and antisense strands, and
hence, there are two measurements for each base in the SARSCoV-2 genome. Since the genome consists of ∼30 000 bases,

serves as a probe. Each column of the array is divided into
probe sets of four features. Within each probe set, each feature
consists of ssDNA with a sequence that matches the same
portion of the genome except for the 13th base, which always
contains an A in the ﬁrst feature, T in the second, and C and G
in the third and fourth, respectively (Figure 1). The probe sets
are arranged in rows such that in one row the sequences in
successive probe sets tile across the genome and match the
genome except for the 13th base (for which only one feature
within the set has the matching base) (Figure 1E). The feature
within the set that matches the genome sequence will hybridize
with the genome fragment. The genome fragments are each
tagged with a ﬂuorescent molecule so that in a ﬂuorescence
4768
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the tiling array possesses approximately 240 000 discrete
features (∼30 000 bases × 2 strands × 4 features per base).
In addition to the genome tiling features, the arrays also
contain alignment marks and several control features for
human sequences.
Illustration of the Approach by Sequencing of the N1
Gene Sequence. As an initial test, we ampliﬁed a region of
the N1 and N2 genes in the SARS-CoV-2 genome
(synthesized by Twist Biosciences) using the N1 and N2
CDC primer pairs obtained from Integrated DNA Technologies (Supporting Information, Table S1). The PCR products
were labeled and hybridized to the tiling array, as described in
the Experimental Section. The arrays were imaged using a
custom-automated ﬂuorescent scanning confocal microscope.
The ﬂuorescence intensity and x,y coordinates of each feature
were stored in a. csv ﬁle and mapped to each base in the N1
and N2 gene regions of the SARS-CoV-2 genome.
The intensities from the features containing each of the four
features for each base position were ranked {I0 ≤ I1 ≤ I2 ≤ I3}.
To call the base, we deﬁne two parameters that characterize
the quality or conﬁdence in the call: the diﬀerence (D = I3 −
I −I
I0) and diﬀerential (drel = 3 D 2 ). Each base is called by
identifying the feature with the highest intensity for both the
sense and antisense features. The base call was typically
consistent between the sense and antisense probe sets.
However, if they are inconsistent, the probe set with the
higher diﬀerential is selected as the ﬁnal call. Using this
approach, we were able to sequence the N1 and N2 regions of
the SARS-CoV-2 genome with 100% accuracy.
Resequencing the Full SARS-COV-2 Genome. We
extended the above technique to sequence all ∼30 000 bases
of the SARS-CoV-2 genome. We obtained eight SARS-CoV-2positive clinical samples from the Wyoming Public Health
Laboratory, which were blinded prior to resequencing (the
samples were unblinding after the base calling was complete).
The viral genome in these clinical samples was previously fully
sequenced on an Illumina MiSeq instrument, and the results
were deposited in the GISAID database. Thus, the sequences
obtained from our genome tiling arrays can be directly
compared with those obtained from Illumina sequencing. The
samples we analyzed were USA/WY-WYPHL-00024/2020,
USA/WY-WYPHL-00026/2020, USA/WY-WYPHL-00032/
2020, USA/WY-WYPHL-00036/2020, USA/WY-WYPHL00041/2020, USA/WY-WYPHL-00044/2020, USA/WYWYPHL-00059/2020, and USA/WY-WYPHL-00064/2020.
We will simply refer to these samples as WY24, WY26,
WY32, WY36, WY41, WY44, WY59, and WY64, respectively.
By the time we acquired these samples, there was a limited
amount of material remaining because the samples had already
been tested via a standard qPCR clinical test at the Wyoming
Public Health Laboratory and had the complete genome
sequenced at the University of New Mexico. Therefore, to
resequence the genome from these samples using our genome
tiling array, we started with the remaining PCR products that
were ampliﬁed with the ARTIC SARS-CoV-2 v3 primer sets
(the sample names were blinded) (Table S1). We further
ampliﬁed the samples with labeled dUTP and then hybridized
the puriﬁed PCR products to the SARS-CoV-2 genome tiling
arrays, as described in the Experimental Section.
Maximum Likelihood Method to Accurately Sequence the SARS-CoV-2 Genome. The method described
above was suﬃcient for analyzing the N1 and N2 PCR

Article

products but was only able to resequence the full SARS-CoV-2
genome to ∼98−99% accuracy. Therefore, we developed a
more sophisticated maximum likelihood method for calling
each base in the SARS-CoV-2 genome. We also noticed that
the intensity of the probe sets varied across the entire genome,
so we scanned the tiling array with three diﬀerent exposure
times (0.5, 1, and 4 s). The longer exposure times enabled us
to accurately call bases in the “weak” intensity regions;
however, the “brighter” regions were fully saturated by the
longer exposures. In principle, one could combine the three
diﬀerent exposures of the same base position into a single,
normalized intensity and call the base with the highest value.
However, the resulting integrated reads would still have to be
combined for the sense and antisense probe sets, and
conﬂicting calls would require a likelihood-based criterion.
This prompted us to adopt an approach that treats the NE = 3
exposures as quasi-independent “reads”. We assigned a
credibility score to each read based on the diﬀerence, D, and
diﬀerential, drel, of the intensities, as illustrated in Figure 2.
Brieﬂy, for each of the probe sets for a given base location in
the genome, we sorted the intensities from the four bases (or
features), identiﬁed a tentative call (the feature with the
highest intensity), and computed D,drel. We grouped the base
calls or reads for all sense and antisense probe sets for each
base in the genome for each exposure into likely “correct” and
incorrect by comparing the tentative call with the SARS-CoV-2
genome reference sequence and constructed separate density
maps in the D,drel plane for the correct (reference matching)
and incorrect (nonmatching) calls (Figure 2A,B). While D and
drel correlate individually with a higher likelihood of correct
calls, the two-dimensional densities reveal a pattern where the
correct and incorrect calls are concentrated in largely
nonoverlapping regions. We developed an approach that
takes advantage of this feature. A read with parameters
(D,drel) is assigned a score, S = wcorrect/(wcorrect + wincorrect),
where wcorrect is based on the number of reads with D′ < D and
d′rel < drel, and wincorrect is the number of likely incorrect reads
with higher D′,d′rel. The score is calculated eﬃciently for every
read of every base using a 2D histogram of the distributions of
correct and incorrect calls and then computing the cumulative
sums for each bin. Reads for a given location are sorted by
their score, and the ﬁnal call is made consistent with the topscoring read.
Analysis of Resequencing Accuracy from USA/WYWYPHL-00064/2020. Using the maximum likelihood method described above, we resequenced the SARS-CoV-2 genome
from eight clinical samples from the Wyoming Public Health
Laboratory. The probability, P, of an incorrect call was
determined for each base in the genome. The “Phred scores”,
Q (Q =−10 log10 P), versus genome coordinates for WY64 are
shown in Figure 3 (similar ﬁgures for all samples are in the
Supporting Information, Figures S25−S32). In WY64, there
were 183 bases with a Phred score less than 20 (81% of these
calls were correct). The short read Illumina sequencing
assembly of this sample consisted of 246 Ns or uncalled
bases. We ﬁltered the 181 uncalled bases from the assembly
and therefore called 29 663 bases (Table 1). Of these called
bases, 27 were identiﬁed as variants (or nonreference calls). Of
the 27 variant calls, we correctly detected eight variants in
WY64 that were identiﬁed by Illumina short read sequencing
(at positions 241, 1059, 3037, 12 756, 14 408, 23 403, 23 453,
25 563); therefore, if we assume that all other bases in this
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and constructed a tiled genome array for rapid and inexpensive
SARS-CoV-2 genome resequencing. We have resequenced
eight clinical samples to demonstrate the ability of this array to
accurately sequence over 95% of the viral genome. Additionally, we have shown that the primary variable limiting our
accuracy and sequencing coverage is the ARTIC multiplex
PCR primer sets, which do not amplify all amplicons with
suﬃcient eﬃciency. Therefore, with improved ampliﬁcation of
the viral genome, we anticipate that over 99% of the genome
can be sequenced with an accuracy greater than 99.9% using a
genome tiling array.

genome are consistent with the reference genome, we made 19
sequencing errors, which is equivalent to 99.94% accuracy.
Next, we further investigated the sequencing errors and
found that seven errors were made in the 100 base region
beginning at position 19 417. This region is within the larger
region that contained the bases that were not called from the
Illumina short read sequencing data due to low sequencing
coverage (Figure 3). Since we started with the same original
PCR products, we ﬁltered variants called by our tiling array
within the six regions in the genome with the lowest short read
coverage, with the reasoning that the ARTIC SARS-CoV-2 v3
primer sets may not be providing adequate ampliﬁcation of the
respective amplicons in these regions. After ﬁltering calls in
these regions, we still called all eight of the variants identiﬁed
from the Illumina sequencing data, as well as nine additional
variants that are presumably incorrect, which resulted in
99.97% sequencing accuracy spanning 95.8% of the SARSCoV-2 genome. Equivalent results for all eight sequenced
strains are shown in Table 1 (ﬁgures equivalent to Figure 3 for
all samples are available in the Supporting Information, Figures
S25−S32).
Low-Quality Assembled Regions from the Tiling
Array. In the GISAID database, the WY64-assembled
FASTA ﬁle contains “Ns” in the region between 19 300 and
19 547. This is consistent with the region of the genome that
had the lowest short read sequencing coverage. In this region,
after ﬁltering the base calls with a Phred score below 20, our
genome tiling array called 167 bases, and 160 of these bases
matched the reference base. We also detected seven putative
variants called by the tiling array with a Q-score higher than
20. Next, we blasted the 248 base consensus sequence (the
region unassembled from the Illumina data, without ﬁltering
any bases) assembled from the tiling array against the SARSCoV-2 reference (NC_045512) and found our sequence to be
94% similar to the reference, with 24 mismatches. This
indicates that our genome tiling array can accurately identify
the sequences as SARS-CoV-2 even with very little starting
material.
We further explored the impact of low amplicon abundance
(measured by low coverage in the Illumina short read data) by
analyzing the Phred score we obtained from the genome tiling
array. In Figure 4A, we plot positions within the genome,
where variants are called within the SARS-CoV-2 genome. It
can be seen in this ﬁgure that variants are called at a high
density at a few discrete locations within the genome. Some of
these locations are known to have low coverage in the Illumina
short read sequencing data and are thus presumed to have
poor ampliﬁcation of the respective amplicons (Figure 4B). To
further explore the ampliﬁcation of these regions of the
genome, we plotted the maximum signal intensity from each
probe set for each position in the genome. Figure 4C focuses
on the region discussed above (between positions 19 300 and
19 547), and it can be seen that the signal intensity is reduced
in this region of the genome, which is consistent with the low
short read sequencing coverage in this region.
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